The biotech will cut 180 positions, or about two-thirds of its workforce, and discontinue development of its lead drug ...

PNN New Delhi [India] December 3 SOHM Inc a globally recognised pharmaceutical company focused on developing manufacturing ...

In a report released yesterday, Alec Stranahan from Bank of America Securities reiterated a Buy rating on Agios Pharma (AGIO – Research ...

Editas Medicine faces a downgrade to Underperform from BofA, citing competition, limited catalysts, and a reduced price ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Vertex Pharmaceuticals Incorporated looks set for two new drug approvals in early 2025. Click here to read an analysis of ...

Researchers at the meeting reported on long-term activity of commercialized gene therapies and preliminary data on ...

The firm has a target price for Gilead of $125 ... Outside of CF, it sees the sickle cell disease and transfusion-dependent β-thalassemia gene therapy Casgevy (exagamglogene autotemcel ...

Fintel reports that on December 9, 2024, Jefferies upgraded their outlook for Vertex Pharmaceuticals (NasdaqGS:VRTX) from ...

The biotech industry has lagged the broader market so far in 2024. The SPDR S&P Biotech ETF, an industry benchmark, is up 9% ...

Beam Therapeutics (NASDAQ:BEAM – Get Free Report)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright ...